New diabetes pill shows promise in Mid-Stage trial
NCT ID NCT07321678
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental tablet called ASC30 in 100 adults with type 2 diabetes. The goal is to see if it safely lowers blood sugar and helps with weight over 13 weeks compared to a placebo. Participants must have stable weight and a BMI of 23 or higher.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Have Type 2 Diabetes (T2D) * Have HbA1c ≥7.0% to ≤10.5% as determined by the central laboratory at screening. * Stable body weight (less than 5% self-reported change within the previous 3 months). * Have a BMI ≥23.0 kilogram/square meter (kg/m²) at screening. Exclusion Criteria: * Have any prior diagnosis of type 1 diabetes mellitus (T1DM), or rare forms of diabetes mellitus * Have had more than 1 episode of severe hypoglycemia * Have poorly controlled hypertension * Have acute or chronic hepatitis and pancreatitis * Have evidence of a significant active and uncontrolled medical condition
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM (type 2 diabetes mellitus) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ascletis Clinical Site
Riverside, California, 92506, United States
-
Ascletis Clinical Site
San Jose, California, 95128, United States
-
Ascletis Clinical Site
Denver, Colorado, 80246, United States
-
Ascletis Clinical Site
Miami, Florida, 33143, United States
-
Ascletis Clinical Site
Miami, Florida, 33172, United States
-
Ascletis Clinical Site
Decatur, Georgia, 30030, United States
-
Ascletis Clinical Site
Springfield, Missouri, 65802, United States
-
Ascletis Clinical Site
San Antonio, Texas, 78240, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Once-Weekly shot tame type 2 diabetes blood sugar?
- Can an Anti-Inflammatory diet tame type 2 diabetes?
- New diabetes combo pill aims to beat single drugs in major trial
- New combo therapy aims to improve diabetes management
- New triple therapy aims to protect kidneys in diabetes patients
- New combo diabetes pill tested in healthy volunteers